Atai Life Sciences ATAI and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).Patients were given an 8 mg dose of BPL-003 followed by a 12 mg dose two weeks later.Key FindingsFollowing the first (8 mg) dose, patients experienced a mean MADRS (Montgomery-Asberg Depression Rating Scale) reduction of ...